Filing Flows › Agios Pharmaceuticals (AGIO) › Q2 2026 › vs Q2 2025
Agios Pharmaceuticals (AGIO) Q2 2026 vs Q2 2025 (year over year)
Agios Pharmaceuticals's revenue rose $32.3M (+259%) from $12.5M in Q2 2025 to $44.7M in Q2 2026.
Agios Pharmaceuticals, Q2 2026: revenue $44.7M (+259% year over year), operating margin -247.1%, net loss $101M, operating cash flow −$57.3M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $44.7M | $12.5M | $32.3M | +259% |
| Other income, net | $9.8M | $15.0M | −$5.2M | -34% |
| Net loss | $101M | $112M | −$11.3M | -10% |
| Costs & expenses | $155M | $140M | $15.8M | +11% |
| Operating costs | $155M | $140M | $15.8M | +11% |
| Cost of revenue | $3.0M | $1.7M | $1.3M | +76% |
| Research & development | $101M | $91.9M | $8.8M | +10% |
| SG&A | $51.5M | $45.9M | $5.7M | +12% |
| Operating cash sources | $101M | $112M | −$11.3M | -10% |
| Share-based compensation | $15.9M | $14.7M | $1.2M | +9% |
| Working capital & other | $27.4M | $20.2M | $7.2M | +36% |
| Cash used in operations | $57.3M | $77.1M | −$19.8M | -26% |
| Net loss absorbed | $101M | $112M | −$11.3M | -10% |
Questions
How much did Agios Pharmaceuticals's revenue grow year over year in Q2 2026?
Agios Pharmaceuticals's revenue rose $32.3M (+259%) from $12.5M in Q2 2025 to $44.7M in Q2 2026.